-
Product Insights
NewSubstance P Receptor – Drugs In Development, 2024
The Substance P Receptor pipeline drugs market research report outlays comprehensive information on the Substance P Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Toxicology, Central Nervous System, Undisclosed, and Infectious Disease which include indications of Chemotherapy Induced Nausea and Vomiting, Pulmonary Radiation Toxicity , Traumatic Brain Injury, Intracranial Hypertension, Unspecified, Bacterial Infections, and Influenza A...
-
Product Insights
NewP Selectin Glycoprotein Ligand 1 – Drugs In Development, 2024
The P Selectin Glycoprotein Ligand 1 pipeline drugs market research report outlays comprehensive information on the P Selectin Glycoprotein Ligand 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Gastrointestinal, Oncology, and Respiratory which include indications of Autoimmune Disorders, Inflammation, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Solid Tumor, Melanoma, Asthma, and Acute Respiratory Distress Syndrome. It...
-
Innovation Ranking
Innovation Ranking – S&P Global Inc
S&P Global Inc (SPGI) is a provider of financial intelligence solutions. It offers credit ratings, benchmarks, data, and digital and traditional financial research and analytical tools to the capital and commodity markets globally. The company provides cross-asset analytics, multi-asset-class data, benchmark prices, desktop services, and investment information. SPGI is a provider of information and benchmark prices for the commodity and energy markets. It also maintains various valuation and index benchmarks for wealth managers, investment advisors, and institutional investors. The company...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Ovarian Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Colorectal Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Gastric Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Solid Tumor Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Esophageal Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Pancreatic Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Follicular Lymphoma Drug Details: P-CD19CD20-ALL01 is under development for...